First Turn Management LLC Sells 21,628 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

First Turn Management LLC reduced its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 16.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,222 shares of the company’s stock after selling 21,628 shares during the period. Krystal Biotech comprises 3.3% of First Turn Management LLC’s holdings, making the stock its 10th biggest position. First Turn Management LLC’s holdings in Krystal Biotech were worth $20,058,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in KRYS. Charles Schwab Investment Management Inc. boosted its holdings in shares of Krystal Biotech by 2.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 185,038 shares of the company’s stock valued at $22,956,000 after acquiring an additional 5,258 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Krystal Biotech by 34.7% during the fourth quarter. BNP Paribas Financial Markets now owns 39,072 shares of the company’s stock worth $4,847,000 after buying an additional 10,057 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Krystal Biotech by 5.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 550,806 shares of the company’s stock worth $68,337,000 after buying an additional 30,169 shares in the last quarter. Fiera Capital Corp purchased a new stake in Krystal Biotech during the fourth quarter worth $1,973,000. Finally, Quest Partners LLC purchased a new stake in Krystal Biotech during the fourth quarter worth $127,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $195.64 on Friday. The firm has a market cap of $5.62 billion, a PE ratio of 104.62 and a beta of 0.82. The company has a 50-day moving average of $195.69 and a two-hundred day moving average of $178.27. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The business had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same quarter last year, the firm posted ($1.25) earnings per share. The business’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on KRYS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Chardan Capital increased their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Evercore ISI increased their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Citigroup reiterated a “neutral” rating and issued a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $196.75.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).